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Abstract
Objective: The CHIMES Study compared MLC601 to placebo in patients with
ischemic stroke of intermediate severity in the preceding 72 hours. We aimed to
verify if patient selection based on two prognostic factors (ie, stroke severity and
time to treatment) improves detection of a treatment effect with MLC601.
Methods: Analyses were performed using data from the CHIMES Study, an inter-
national, randomized, placebo-controlled, double-blind trial comparing MLC601
to placebo in patients with ischemic stroke of intermediate severity in the preced-
ing 72 hours. Three subgroups, that is, onset to treatment time (OTT) 48 hours;
baseline National Institute of Health Stroke Scale (NIHSS) 10; both OTT 48
hours and baseline NIHSS10, were analyzed using modified Rankin Scale (mRS)
1 and a composite endpoint of mRS 1, Barthel Index 95, and NIHSS 1 at
month 3.
Results: Placebo response rates were lower (ie, worse natural outcome)
among subgroups with prognostic factors. Conversely, MLC601 treatment effects
were significantly higher in the subgroups with prognostic factors than for the en-
tire cohort, being highest among patients with both OTT 48 hours and baseline
NIHSS of 10 to 14: odds ratios of 2.18 (95% CI 1.02 to 4.65) for month 3 mRS1
and 3.88 (95% CI 1.03 to 14.71) for the composite endpoint.
Conclusions: : Patients who have moderately severe strokes and longer OTT
demonstrate better treatment effects with MLC601. These factors can guide pa-
tient selection in future trials.
Introduction
MLC601 (NeuroAiD), a product combining herbal and non-
herbal extracts, has been shown to have neuroprotective and
neurorestorative properties in cellular and animal ischemic
models (1). Early clinical trials in patients with non-acute
stroke have shown benefits in improving neurological and
functional outcomes (2). In the Chinese Medicine Neuroaid
Efficacy on Stroke recovery Study (CHIMES), we investi-
gated the use of MLC601 in acute stroke within 72 hours of
onset (3). We recently published a preplanned analysis which
showed larger treatment effects of MLC601 in both primary
and secondary outcomes in the Philippine cohort compared to
the treatment effects in the overall CHIMES study cohort (4).
We hypothesized that this may have been due to inclusion
of more women, relatively more severe strokes, and longer
delays from stroke onset to treatment time (OTT) among
Filipino patients than those included from other countries.
Increasing age, female sex, stroke severity and OTT 48
hours were found to be predictive factors of poorer outcome,
the presence of which may enhance the detection of treatment
effect in the CHIMES Study (5).
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In this analysis, we aimed to verify if selection of pa-
tients according to two important prognostic factors, that is,
baseline stroke severity and delay in treatment, would show
larger treatments effects of MLC601 in the CHIMES cohort.
We focused on these two particular factors because they can
reasonably be incorporated in selection criteria of clinical
trials, as well as due to their plausible effects on outcome
after stroke.
Methods
Analyses were performed using data from the CHIMES
Study, an international, randomized, placebo-controlled,
double-blind trial that compared MLC601 to placebo in 1099
patients with ischemic stroke of intermediate severity (Na-
tional Institute of Health Stroke Scale, NIHSS, 6 to 14) in the
preceding 72 hours (clinicaltrials.gov NCT00554723) (3).
Patients were allocated to either MLC601 or placebo for
3 months as add-on to standard stroke care (ie, antiplatelet
therapy, control of vascular risk factors, appropriate rehabil-
itation) and followed for 3 months. The study was approved
by the Ethics Committee of each site and all subjects gave
informed consent prior to participation.
Subjects with actual month 3 outcomes were included in
the analyses of the overall cohort and three subgroups ac-
cording to the presence of two prognostic factors of poorer
outcome: OTT 48 hours, baseline NIHSS 10 to 14, and
both OTT 48 hours and baseline NIHSS 10 to 14. The pri-
mary outcome measure used was the modified Rankin score
(mRS) at month 3. Since the CHIMES study included pa-
tients with relatively less severe stroke (3), we also used a
composite endpoint of mRS1, Barthel Index (BI)95, and
NIHSS1 to define excellent outcome representing minimal
or no poststroke deficit which was used in other acute stroke
trials (6–8).
Odds ratios (OR) and the corresponding 95% confidence
intervals (CI) were used to estimate treatment effects (mRS of
0 or 1 and composite outcome) in a logistic regression model
after adjusting for age and sex which were also predictors of
poorer outcomes in the CHIMES cohort (3–5). The numbers
needed to treat (NNT) to achieve mRS 0 to 1 at month 3
were calculated for each group using the inverse of absolute
differences to estimate the clinical benefit of MLC601.
Results
The baseline characteristics of patients included in CHIMES
were similar between MLC601- and placebo-treated groups
(3). Of the 1099 patients included in the CHIMES Study,
1009 had actual month 3 outcomes assessed, 530 had OTT
48 hours, 363 had baseline NIHSS of 10 to 14, and 201
had both OTT 48 hours and NIHSS of 10 to 14 (Table 1). Ta
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The odds ratio for good outcome, defined as month 3 mRS
1, in the entire cohort was 1.16 (95% CI: 0.90 to 1.49) after
adjusting for age and sex. The OR for each of the analyzed
subgroups reached statistical significance, that is, 1.47 (95%
CI 1.02 to 2.11) in the OTT  48 hours subgroup and 1.71
(85% CI 1.01 to 2.90) in the NIHSS 10 to 14 subgroup,
with the highest treatment effect seen among patients with
both OTT 48 hours and NIHSS of 10 to 14 (OR = 2.18,
95% CI 1.02 to 4.65). The OR for the composite outcome
of mRS 1, BI 95, and NIHSS 1 was similarly highest
and statistically significant for patients with both prognostic
factors (OR = 0.88, 95% CI 1.03 to 14.71).
The proportion of good outcome decreased with the pres-
ence of prognostic factors in the MLC601-treated group
(44.2% in the OTT 48 hours subgroup, 28% in the NIHSS
10 to 14 subgroup) and was lowest (25%) among patients
with both prognostic factors. By comparison, the reduction
in good outcome was more pronounced in the placebo group
(35.3% in the OTT48 hours subgroup, 18.5% in the NIHSS
10 to 14 subgroup, 13.5% in the group with both prognos-
tic factors). This led to larger absolute differences in favor
of MLC601 (8.9% in the OTT 48 hours subgroup, 9.5%
in the NIHSS 10 to 14 subgroup) and corresponding lower
NNT (11 in the OTT 48 hours subgroup, 10 in the NIHSS
10 to 14 subgroup) which were best demonstrated in patients
with both prognostic factors (absolute difference of 11.5%,
NNT = 9).
Discussion
Our study used actual clinical trial data to demonstrate the
importance of proper selection of patients with potential to
benefit in clinical trials (9–11). The variables we analyzed,
OTT and NIHSS, represent important inherent treatment-
related (ie, mode of action) and disease-related (ie, prognosis)
factors to consider when designing studies.
Stroke is a devastating disease. The aim of treatment is to
restore as much of the resulting neurological and functional
impairments as possible. Recovery from stroke, however, de-
pends significantly on how much tissue is saved by reversing
the injurious process (eg, revascularization) and severity of
the deficits after the tissue damage.
To date, the only approved pharmacological treatment for
acute ischemic stroke is intravenous thrombolysis by re-
combinant tissue plasminogen activator (rt-PA). rt-PA has
been shown to improve outcomes of survival and indepen-
dence (7, 8, 12–15). However, its use is limited by the very
short window of opportunity for treatment and risk of bleed-
ing, making less than 6% of stroke patients eligible for such
treatment (16, 17). In a pooled analysis, the NNT for achiev-
ing an mRS score of 0 to 1 was 4.5 for OTT of <90 min-
utes, 9 for OTT 91 to 180 minutes, and 14 for OTT 181 to
270 minutes (8). Median baseline NIHSS scores were 15, 13,
and 10, respectively. For rt-PA, the sooner the treatment is
given, the better. The most recent meta-analysis showed that
despite early increases in fatal intracranial haemorrhage, al-
teplase significantly improves the overall likelihood of good
outcome (mRS<1), with the proportional benefits increasing
with earlier treatment (15).
On the other hand, our study showed that in the CHIMES
cohort, patients with OTT 48 hours paradoxically have
better treatment effects than in the overall cohort with NNT
comparable to that of rt-PA. This may not be as surprising
since the therapeutic effects of rt-PA (ie, revascularization) is
most relevant during the hyperacute phase of stroke, while the
putative mechanism of action of MLC601 (ie, neurorestora-
tion) is more important at a later stage after brain injury. In
addition, patients who arrive for treatment much later after a
stroke have generally poorer prognosis (18), which is another
important factor in demonstrating treatment effects.
Stroke is a heterogeneous condition and the deficits are
variable. Prognosis for natural recovery can be different de-
pending on severity, with mild strokes expected to recover
remarkably and more severe ones recovering only to a certain
extent (19). In trials wherein clinical measures are used to de-
tect therapeutic effects, treatment benefit may not be demon-
strated as obviously in those who would spontaneously re-
cover fully regardless of intervention and in those who are
too severe to realistically expect significant improvement.
The three subgroups we analyzed in this study showed
placebo response rates that appear to be inversely related
to the OR, implying higher treatment effects with MLC601
among patients with worse prognosis. A high response rate in
the placebo arm can affect the potential of detecting treatment
effects in clinical trials (20–22). In the CHIMES study, almost
half in the placebo group achieved functional independence
(mRS 0 to 1) at the end of 3 months. By selecting patients
with relatively more severe NIHSS in the current analysis,
the lower placebo response rate allowed for better detection
of differences despite a smaller sample size. The even larger
effects seen by the combination of more severe NIHSS and
longer OTT further suggests that inclusion of stroke patients
at a time when their deficits are more established and un-
likely to fluctuate can help identify a population with more
homogenous prognosis among whom treatment effects can
be better seen. It further supports the theory that in recovery
trials, the sample size required to detect improvement may
be reduced as severity and time since stroke increases (19).
In terms of safety, we have previously shown com-
parable rates of non-serious and serious adverse events,
including intracerebral and gastrointestinal hemorrhage, be-
tween MLC601 and placebo groups (3).
There are some limitations in this study. This is a post
hoc analysis. In addition, the source study population was
restricted only to patients with NIHSS of 6 to 14 and stroke
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onset within 72 hours of randomization and findings may
not be applicable to patients outside these criteria. However,
the data used were collected prior to unblinding and were
obtained from a randomized double-blind large clinical trial
with a high quality of follow-up.
Numerous stroke trials, including the use of neuroprotec-
tive drugs, have met many difficulties in translating signifi-
cant findings in preclinical models to clinical benefits as mea-
sured in clinical trials (23). The reasons for this failure have
been extensively discussed (24–26). Clinically, patient selec-
tion may be among the most important factors that should
be considered when designing trials in stroke. While every
effort must be made to have adequate demographic repre-
sentation (eg, age, sex, race–ethnicity, etc) in clinical trials,
there are treatment- and disease-specific eligibility factors
that may be important in achieving a more homogeneous
study population.
Conclusions
Our study shows that selection of patients who have mod-
erately severe strokes and delay in OTT demonstrates better
treatment effects with MLC601, which can become valu-
able particularly for those who are ineligible to receive in-
travenous thrombolysis or do not significantly respond to
treatment in the acute phase. Together with the understand-
ing of time window when the intervention is most likely to
be effective, these variables are valid targets to guide patient
selection in future ischemic stroke trials in order to reduce
sample sizes.
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